Skip to main content
. 2017 Jun 8;1:19. doi: 10.1038/s41698-017-0023-0

Fig. 7.

Fig. 7

APX3330 has broad potential in a variety of cancers. Supportive pre-clinical data exists for APX3330 in combination with each drug listed in the diagram (yellow boxes) and for each indication (red boxes). The asterisk symbol indicates that in addition to anti-tumor activity, APX3330 provides neuroprotection when administered with agents causing oxidative damage to neurons. Definitive developmental plans await results of Phase I study and discussions with key opinion leaders